U.S. Trial With AstraZeneca's Coronavirus Vaccine Expected to Resume Soon
Clinical trials with an experimental coronavirus vaccine from AstraZeneca (NYSE: AZN) that was put on pause over a month ago could start up again soon in the United States. Trials with the candidate, AZD1222, were paused on Sept. 6, after a clinical trial volunteer in the U.K. experienced an adverse event.
In response, regulators around the globe swiftly paused enrollment into clinical trials with AZD1222, a SARS-CoV-2 vaccine that AstraZeneca licensed from Oxford University. Studies with AZD1222 in the U.K. resumed less than one week later.
Image source: Getty Images.
Source Fool.com
